NO20050937L - Indoline derivatives substituted at position 6, preparation and use thereof as drugs - Google Patents

Indoline derivatives substituted at position 6, preparation and use thereof as drugs

Info

Publication number
NO20050937L
NO20050937L NO20050937A NO20050937A NO20050937L NO 20050937 L NO20050937 L NO 20050937L NO 20050937 A NO20050937 A NO 20050937A NO 20050937 A NO20050937 A NO 20050937A NO 20050937 L NO20050937 L NO 20050937L
Authority
NO
Norway
Prior art keywords
drugs
preparation
derivatives substituted
indoline derivatives
various
Prior art date
Application number
NO20050937A
Other languages
Norwegian (no)
Inventor
Armin Heckel
Gerald Juergen Roth
Ulrike Tontsch-Grunt
Frank Hilberg
Thorsten Lehmann-Lintz
Jorg Kley
Jacobus C A Van Meel
Original Assignee
Boehringer Ingelheim Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE10233366A external-priority patent/DE10233366A1/en
Priority claimed from DE10328533A external-priority patent/DE10328533A1/en
Application filed by Boehringer Ingelheim Pharma filed Critical Boehringer Ingelheim Pharma
Publication of NO20050937L publication Critical patent/NO20050937L/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
    • C07D209/32—Oxygen atoms
    • C07D209/34—Oxygen atoms in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Dermatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Indole Compounds (AREA)

Abstract

Foreliggende oppfinnelse angår indollnon-derlvater, substituert i 6-stllllng, med formelen hvor R^ til R* og X er som definert i krav 1, deres tautomerer, enantiomerer, diastereo- merer, deres blandinger og deres salter, spesielt deres fysiologisk akseptable sal- ter, som har anvendelige farmakologiske egenskaper, spesielt en hemmende virkning på forskjellige reseptor-tyroslnkinaser og på proliferasjonen av endotelcel- ler og forskjellige tumorceller, medikamenter omfattende disse forbindelser, an- vendelse av dem, og fremgangsmåter for fremstilling av dem.BACKGROUND OF THE INVENTION 1. Field of the Invention The present invention relates to indole derivatives substituted in 6-position, with the formula wherein R - drugs having useful pharmacological properties, in particular an inhibitory effect on various receptor tyrosine kinases and on the proliferation of endothelial cells and various tumor cells, drugs comprising these compounds, their use, and methods for their preparation.

NO20050937A 2002-07-23 2005-02-21 Indoline derivatives substituted at position 6, preparation and use thereof as drugs NO20050937L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE10233366A DE10233366A1 (en) 2002-07-23 2002-07-23 Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
DE10328533A DE10328533A1 (en) 2003-06-24 2003-06-24 New 6-amino-substituted indolinone derivatives, useful e.g. for treating tumours and angiogenesis, are inhibitors of receptor tyrosine kinases
PCT/EP2003/007961 WO2004009547A1 (en) 2002-07-23 2003-07-22 Indoline derivatives substituted in position 6, production and use thereof as medicaments

Publications (1)

Publication Number Publication Date
NO20050937L true NO20050937L (en) 2005-02-21

Family

ID=30771725

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20050937A NO20050937L (en) 2002-07-23 2005-02-21 Indoline derivatives substituted at position 6, preparation and use thereof as drugs

Country Status (25)

Country Link
EP (1) EP1523473B1 (en)
JP (1) JP4401291B2 (en)
KR (2) KR20050052456A (en)
CN (1) CN1318403C (en)
AR (1) AR041188A1 (en)
AU (2) AU2003254557B2 (en)
BR (1) BR0312799A (en)
CA (1) CA2493436C (en)
DK (1) DK1523473T3 (en)
EA (1) EA008623B1 (en)
EC (1) ECSP055567A (en)
ES (1) ES2409062T3 (en)
HK (1) HK1081554A1 (en)
HR (1) HRP20050069A2 (en)
IL (1) IL166404A0 (en)
MX (1) MXPA04012937A (en)
MY (1) MY138141A (en)
NO (1) NO20050937L (en)
PE (1) PE20040701A1 (en)
PL (2) PL397821A1 (en)
RS (1) RS20050047A (en)
SA (1) SA03240430B1 (en)
TW (1) TWI343375B (en)
UY (1) UY27903A1 (en)
WO (1) WO2004009547A1 (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7169936B2 (en) 2002-07-23 2007-01-30 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6-position, their preparation and their use as medicaments
US7514468B2 (en) 2002-07-23 2009-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Indolinone derivatives substituted in the 6 position, the preparation thereof and their use as pharmaceutical compositions
US20060058311A1 (en) * 2004-08-14 2006-03-16 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation
PE20061155A1 (en) * 2004-12-24 2006-12-16 Boehringer Ingelheim Int INDOLINONE DERIVATIVES AS AGENTS FOR THE TREATMENT OR PREVENTION OF FIBROTIC DISEASES
KR20080007645A (en) 2005-04-28 2008-01-22 베링거 인겔하임 인터내셔날 게엠베하 Novel compounds for treating inflammatory diseases
WO2007057399A2 (en) * 2005-11-15 2007-05-24 Boehringer Ingelheim International Gmbh Treatment of cancer with indole derivatives
CN101925577A (en) * 2008-01-25 2010-12-22 贝林格尔.英格海姆国际有限公司 Salt forms of 6-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene derivative, process for their manufacture and pharmaceutical compositions containing same
AU2009207861A1 (en) * 2008-01-25 2009-07-30 Boehringer Ingelheim International Gmbh Process for the manufacture of a 6-fluoro-1,2-dihydro-2-oxo-3H-indol-3-ylidene derivative
MX2011000730A (en) 2008-07-29 2011-03-15 Boehringer Ingelheim Int New compounds.
US9512075B2 (en) 2012-10-17 2016-12-06 Okayama University Compound; tautomer and geometric isomer thereof; salt of said compound, tautomer, or geometric isomer; method for manufacturing said compound, tautomer, isomer, or salt; antimicrobial agent; and anti-infective drug
JP6207625B2 (en) 2012-12-06 2017-10-04 山東亨利醫藥科技有限責任公司 Indolinone derivatives as tyrosine kinase inhibitors
CN105461609B (en) * 2015-12-25 2019-08-23 杭州新博思生物医药有限公司 A kind of preparation method of Nintedanib
CN114213396B (en) * 2022-01-27 2023-03-24 深圳市乐土生物医药有限公司 Indole-2-ketone compound and preparation method and application thereof

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL141622A0 (en) * 1998-09-25 2002-03-10 Boehringer Ingelheim Pharma Novel substituted indolinones with an inhibitory effect on various kinases and cyclin/cdk complexes
GB9904933D0 (en) * 1999-03-04 1999-04-28 Glaxo Group Ltd Compounds
AU2002341881B2 (en) * 2001-09-27 2008-05-08 Allergan, Inc. 3-(arylamino)methylene-1, 3-dihydro-2h-indol-2-ones as kinase inhibitors
US7005444B2 (en) * 2001-09-27 2006-02-28 Allergan, Inc. 3-(heteroarylamino)methylene-1, 3-dihydro-2H-indol-2-ones as kinase inhibitors

Also Published As

Publication number Publication date
PE20040701A1 (en) 2004-11-30
AU2003254557B2 (en) 2010-07-22
PL397821A1 (en) 2012-03-12
ECSP055567A (en) 2005-04-18
CN1318403C (en) 2007-05-30
DK1523473T3 (en) 2013-06-03
JP2005533841A (en) 2005-11-10
IL166404A0 (en) 2006-01-15
PL374879A1 (en) 2005-11-14
TWI343375B (en) 2011-06-11
CN1668589A (en) 2005-09-14
EP1523473B1 (en) 2013-02-27
UY27903A1 (en) 2004-02-27
ES2409062T3 (en) 2013-06-24
BR0312799A (en) 2005-05-03
AU2010202845A1 (en) 2010-07-22
EA008623B1 (en) 2007-06-29
EP1523473A1 (en) 2005-04-20
RS20050047A (en) 2007-09-21
KR20050052456A (en) 2005-06-02
EA200500148A1 (en) 2005-08-25
JP4401291B2 (en) 2010-01-20
CA2493436C (en) 2011-11-08
MY138141A (en) 2009-04-30
MXPA04012937A (en) 2005-05-16
HK1081554A1 (en) 2006-05-19
AU2003254557A1 (en) 2004-02-09
AR041188A1 (en) 2005-05-04
KR20120003025A (en) 2012-01-09
WO2004009547A1 (en) 2004-01-29
HRP20050069A2 (en) 2005-12-31
CA2493436A1 (en) 2004-01-29
TW200413314A (en) 2004-08-01
SA03240430B1 (en) 2008-03-23

Similar Documents

Publication Publication Date Title
NO20050937L (en) Indoline derivatives substituted at position 6, preparation and use thereof as drugs
NO20070917L (en) Imidazotriazines as protein kinase inhibitors
NO20082508L (en) Aminopyrimidines useful as kinase inhibitors
NO20065727L (en) Pyrrole inhibitors of arch-protein kinase, their synthesis and their intermediates
BRPI0512547A (en) pyrimidines
RS20050462A (en) Substituted pyrrolo-pyrazole derivatives as kinase inhibitors
ATE544761T1 (en) PYRIMIDINE DERIVATIVES AND COMPOSITIONS AS C-KIT AND PDGFR KINASE INHIBITORS
EA200901608A1 (en) DERIVATIVES OF CHINAXOLINE AS AN INHIBITORS THYROZINKINASE ACTIVITY OF JANUS KINASE
NO20076659L (en) Pyrrolo (2,3-B) pyridine derivatives as protein kinase inhibitors
NO20091326L (en) Indazole derivatives as modulators of interleukin-1 receptor-associated kinase
ATE469151T1 (en) PYRROLOPYRIDINE DERIVATIVES AS PROTEIN KINASE INHIBITORS
MX2009004807A (en) Aminopyridines and aminopyrimidines useful as inhibitors of protein kinases.
BRPI0514537A (en) pyrazol substituted aminoetheroyl compounds as protein kinase inhibitors
DK1784404T3 (en) Pyrrolo [2,3-c] pyridine derivatives as well as processes for their preparation
NO20070336L (en) Indole derivatives as histamine receptor antagonists
WO2007013896A3 (en) Pyrrol (2,3-b) pyridine derivatives protein kinase inhibitors
NO20084435L (en) C-MET protein kinase inhibitors
NO20073140L (en) Pyrrolopyrazines and pyralopyrazines useful as inhibitors of protein kinases
MX2009002229A (en) Benzotriazole kinase modulators.
BRPI0506802A (en) indole derivatives and their use as kinase inhibitors in particular ikk2 inhibitors
NO20085099L (en) Puriton derivatives such as HM74A agonists
EA200800018A1 (en) AMINOPYRIMIDINES AS KINASE MODULATORS
NO20061981L (en) Arylindenopyridines and arylindenopyridines and their use as adenosine A2A receptor agonist
TW200607805A (en) Novel pyridazinone derivatives, methods for producing them and their use as pharmaceuticals
NO20073113L (en) Indenyl derivatives and their use for the treatment of neurological disorders

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application